Analysis
2019/03/29
Analysis Clinical Pathology A wide range of clinical pathology services are available at INA, conducted by experienced veterinarians (certified clinical chemists) and medical technologists. Pathology At INA, necropsy and histotechnology are performed by well-trained technicians, and histopathological examinations are performed by certified toxicological pathologists, veterinary pathologists and toxicologists. Furthermore, we schedule regular in-house educational seminars, taught by our esteemed advisor of pathology. Metabolism & Chemical Analysis INA offers analyses of test article and dosing formulations, as well as drug concentrations in biological samples. We also offer in vitro and in vivo analysis of hepatic drug-metabolizing enzymes and metabolizing enzyme gene expressions (mRNA).
Health Food Studies
2019/03/29
Health Food Studies Non-clinical Studies Efficacy Studies Below are some examples of the disease model animals available for food efficacy studies. INA also offers free advice and study design planning. Improvement of insulin resistance Reductive effects in hyperlipemia model animals Reductive effects in hypertensive model animals Bone loss inhibitory effects in ovariectomized osteoporosis models and osteopenia models prepared by sciatic neurectomy Improvements to arthritis in arthrorheumatism model animals Antitumor effects Antistress effects Safety Studies All studies are GLP compliant and follow the relevant toxicity study guidelines for pharmaceuticals, as well as Japanese government regulations regarding Food for Specified Health Use (FOSHU, 1998 ). Single dose toxicity Repeated dose toxicity Genotoxicity
Efficacy Studies
2019/03/29
Efficacy Studies INA also specializes in central nervous system and ophthalmology studies. Central nervous system Evaluation of anti-Parkinsonism disease effects Evaluation of anti-pain drugs Evaluation of antipruritic effects – Study on morphine-induced skin scratching Evaluation of anti-ADHD (Attention Deficit Hyperactivity Disorder) effects Circulatory system Evaluation of antihypertension effects Osteology Evaluation of anti-osteoporosis drugs Ophthalmology Evaluation of ocular hypertension drugs and antiglaucoma drugs Evaluation of effects on corneal endothelium deficiency Evaluation of anti-inflammatory drugs Blood glucose Evaluation of antidiabetic drugs Nephritis, renal failure Total Parenteral Nutrition (TPN) Evaluation of nutritional effects of TPN Other Evaluation of antiinflammatory effects Evaluation of suppressive effects on uterine /vaginal atrophy Effects on reproductive organs (weights,
Our Corporation
2019/03/29
A word from the president Corporate Overview Corporate History Offices Head Office Tokyo Office Corporate Governance AAALAC International Compliance Public Research Funds Information Security Policy
Sitemaps
2019/03/23
Sitemaps TOP News Services Pharmaceuticals/Medical Devices Chemicals Agrochemicals Efficacy Studies Health Food Studies Analysis Clinical Pathology Pathology Metabolism & Chemical Analysis Quality Assurance Published Papers Translation Archives Our Corporation From the president Corporate Overview Corporate History Offices Corporate Governance AAALAC InternationalC Compliance Public Research Funds Information Security Policy Contact Us Privacy Policy Disclaim Sitemaps
Information Security Policy
2019/03/22
Information Security Policy 1 Purpose INA established the “Information Security Policy” to protect clients’ and INA’s information assets from risks of leakage, falsification, interference of use, unauthorized access, etc, and to fulfill the social responsibility. INA will promote proper information management and conduct continuous audit and improvement of the information management. 2 Definition of the “information security” The “information secrecy” is defined as the assurance and maintenance of the 1) confidentiality (information must not be leaked), 2) integrity (the content of the information must be accurate with no deficiency), and 3) availability (necessary information can be used as required) of the information. The “information” includes confidential, personal, financial and business
Public Research Funds
2019/03/22
Public Research Funds Ina Research appropriately manages public research funds granted by the Japanese Government under the strict regime of responsibility in which our CEO is the head administrator.
Compliance
2019/03/22
Compliance Declaration of Compliance Toward a true worldwide company In recent years, public awareness of company activities has greatly increased, impacted by the progress of a diversifying and aging society, along with the globalization and digitalization of economic activities. Corporate dishonesty and scandals are no longer permitted, and investors have become more sensitive to a company’s scandals than to their accomplishments. As indicated by recent news, corporate scandal exerts an enormous influence and may cause abrupt fall in the value or even closure of a company. Corporate Social Responsibility (CSR) is the most important task of any company, to enhance the value of the company, and also to win the confidence of society, clients and investors. At Ina Research Inc., we focus on this thorough “Compliance” and “Corporate Governance” as our mainmanagement principles. This “INA Compliance Handbook” includes important matters of compliance. We, the employees of Ina Research Inc., declare to always give top